Evolution of clinical trials in head and neck cancer

Critical Reviews in Oncology/Hematology

Volumn 71, Issue 1, 2009, Pages 29-42

  Yang, Eddy S ^a   Murphy, Barbara M ^a   Chung, Christine H ^a   Netterville, James L ^a   Burkey, Brian B ^a   Gilbert, Jill ^a   Yarbrough, Wendell G ^a,b   Sinard, Robert ^a   Cmelak, Anthony J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoradiation; Clinical trials; Head and neck cancer; Induction chemotherapy; Intensity modulated radiation therapy (IMRT); Larynx cancer; Nasopharynx cancer; Oropharynx cancer; Quality of life

Indexed keywords

ALPHA TOCOPHEROL; AMIFOSTINE; ANTIBIOTIC AGENT; BEVACIZUMAB; CAPSAICIN; CARBOPLATIN; CELLULOSE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GLUTAMINE; INTERFERON; IRINOTECAN; LAPATINIB; METHOTREXATE; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PALIFERMIN; PANITUMUMAB; PEMETREXED; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETINOID; SAFORIS; SORAFENIB; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEAD AND NECK SURGERY; HUMAN; HYPOMAGNESEMIA; HYPOPHARYNX CARCINOMA; INJECTION SITE REACTION; INTENSITY MODULATED RADIATION THERAPY; LARYNX CANCER; MOUTH CARCINOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NUTRITION; ORGAN PRESERVATION; OROPHARYNX CANCER; OROPHARYNX CARCINOMA; PARANASAL SINUS CARCINOMA; POSTOPERATIVE PERIOD; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; SECOND CANCER; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; XEROSTOMIA;

CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; QUALITY OF LIFE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 67349182676     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.09.015     Document Type: Review

References (98)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics 2007. CA Cancer J Clin 57 (2007) 43-66
2. Bryce D.P., and Rider W.D. Pre-operative irradiation in the treatment of advanced laryngeal carcinoma. Laryngoscope 81 (1971) 1481-1490
3. Zorat P.L., Paccagnella A., Cavaniglia G., et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 96 (2004) 1714-1717
4. Kish J., Drelichman A., Jacobs J., et al. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 66 (1982) 471-474
5. Ensley J.F., Jacobs J.R., Weaver A., et al. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 54 (1984) 811-814
6. Hong W.K., Bromer R.H., Amato D.A., et al. Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy. Cancer 56 (1985) 1242-1245
7. Schuller D.E., Metch B., Stein D.W., Mattox D., and McCracken J.D. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope 98 (1988) 1205-1211
8. Wolf G.T., Hong W.K., Fisher S.G., et al., The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324 (1991) 1685-1690
9. Lefebvre J.L., Chevalier D., Luboinski B., Kirkpatrick A., Collette L., Sahmoud T., and EORTC Head and Neck Cancer Cooperative Group. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 88 (1996) 890-899
10. Paccagnella A., Orlando A., Marchiori C., et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86 (1994) 265-272
11. Domenge C., Hill C., Lefebvre J.L., et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 83 (2000) 1594-1598
12. Bourhis J., Le Maitre A., Baujat B., Audry H., and Pignon J.P. Individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol 19 (2007) 188-194
13. Dang TP, Murphy BA, Cmelak A, et al. Carboplatin and taxol as induction therapy for locally advanced carcinoma of the head and neck. Presented at ASCO Annual Meeting, 1998 [abstract #1516].
14. Schoffski P., Weihkopf T., and Ganser A. Advanced head and neck cancer and clinical experience of an effective new agent: docetaxel. Anticancer Res 18 (1998) 4751-4756
15. Dreyfuss A.I., Clark J.R., Norris C.M., et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14 (1996) 1672-1678
16. Schoffski P., Catimel G., Planting A.S., et al., Results of a phase II study of the EORTC Early Clinical Studies Group. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 10 (1999) 119-122
17. Dunphy F.R., Dunleavy T.L., Harrison B.R., et al. Induction paclitaxel and carboplatin for patients with head and neck carcinoma Analysis of 62 patients treated between 1994 and 1999. Cancer 91 (2001) 940-948
18. Schrijvers D., Van Herpen C., Kerger J., et al. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol 15 (2004) 638-645
19. Colevas A.D., Norris C.M., Tishler R.B., et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 17 (1999) 3503-3511
20. Haddad R., Colevas A.D., Tishler R., et al. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer 97 (2003) 412-418
21. Posner M.R., Glisson B., Frenette G., et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19 (2001) 1096-1104
22. Haddad R., Tishler R.B., Norris C.M., et al. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist 8 (2003) 35-44
23. Hitt R., Paz-Ares L., Brandariz A., et al. Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial. Ann Oncol 13 (2002) 1665-1673
24. Colevas A.D., Busse P.M., Norris C.M., et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 16 (1998) 1331-1339
25. Calais G., Pointreau Y., Alfonsi M., et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer Preliminary results of GORTEC 2000-01. J Clin Oncol 24 (2006) 5506 [Meeting Abstracts]
26. Remenar E., Van Herpen C., Germa Lluch J., et al. A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN) Final analysis of EORTC 24971. J Clin Oncol 24 (2006) 5516 [Meeting Abstracts]
27. Posner M, Hershock D, Le-Lann L, Devlin P, Haddad R, TAX 324: A phase III Trial of TPF vs. PF Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced SCCHN. J Clin Oncol (Meeting Abstracts) 2006;24 Scientific special session.
28. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357 (2007) 1705-1715
29. Al-Sarraf M., LeBlanc M., Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16 (1998) 1310-1317
30. Ma J., Mai H.Q., Hong M.H., et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 19 (2001) 1350-1357
31. Chan A.T., Teo P.M., Ngan R.K., et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20 (2002) 2038-2044
32. Chi K.H., Chang Y.C., Guo W.Y., et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 52 (2002) 1238-1244
33. Lin J.C., Jan J.S., Hsu C.Y., Liang W.M., Jiang R.S., and Wang W.Y. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21 (2003) 631-637
34. Zhang L., Zhao C., Peng P.J., et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 23 (2005) 8461-8468
35. Lee A.W., Lau W.H., Tung S.Y., et al., Trial by the Hong Kong Nasopharyngeal Cancer Study Group. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901. J Clin Oncol 23 (2005) 6966-6975
36. Merlano M., Vitale V., Rosso R., et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 327 (1992) 1115-1121
37. Merlano M., Benasso M., Corvo R., et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 88 (1996) 583-589
38. Wendt T.G., Grabenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16 (1998) 1318-1324
39. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003) 92-98
40. Jeremic B., Shibamoto Y., Stanisavljevic B., Milojevic L., Milicic B., and Nikolic N. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 43 (1997) 29-37
41. Denis F., Garaud P., Bardet E., et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22 (2004) 69-76
42. Gupta N.K., and Swindell R. Concomitant methotrexate and radiotherapy in advanced head and neck cancer: 15-year follow-up of a randomized clinical trial. Clin Oncol (R Coll Radiol) 13 (2001) 339-344
43. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
44. Forastiere A.A., Maor M., Weber R.S., et al. Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx-induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol 24 (2006) 5517 [Meeting Abstracts]
45. Taylor S.G.T., Murthy A.K., Vannetzel J.M., et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 12 (1994) 385-395
46. Pignon J.P., Bourhis J., Domenge C., and Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355 (2000) 949-955
47. Munro A.J. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 71 (1995) 83-91
48. El-Sayed S., and Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region A meta-analysis of prospective and randomized trials. J Clin Oncol 14 (1996) 838-847
49. Cmelak A.J., Li S., Murphy B., et al. Locally advanced resectable larynx or oropharynx cancer: Updated results of organ preservation trial ECOG 2399. J Clin Oncol 24 (2006) 5527
50. Cmelak A.J., Murphy B.A., Burkey B., Douglas S., Shyr Y., and Netterville J. Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial. Head Neck 29 (2007) 315-324
51. Cmelak A.J., Li S., Goldwasser M.A., et al. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol 25 (2007) 3971-3977
52. Fakhry C., Westra W., Li S., et al. Prognostic significance of human papillomavirus (HPV) tumor status for patients with head and neck squamous cell carcinoma (HNSCC) in a prospective, multi-center phase II clinical trial. J Clin Oncol 25 (2007) 6000 [Meeting Abstracts]
53. Hitt R., Lopez-Pousa A., Martinez-Trufero J., et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23 (2005) 8636-8645
54. Paccagnella A., Buffoli A., Koussis H., et al. Randomized phase II trial of concomitant CT/RT versus TPF followed by concomitant CT/RT in locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol 24 (2006) 5518 [Meeting Abstracts]
55. Hitt R., Grau J., Lopez-Pousa A., et al. Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 24 (2006) 5515 [Meeting Abstracts]
56. Knecht R., Baghi M., Hambek M., Zamboglou N., and Tesch H. TPF induction chemotherapy followed by concurrent radiochemotherapy in the first line therapy of advanced carcinomas of the larynx and pharynx (phase IIb trial). J Clin Oncol 24 (2006) 5562 [Meeting Abstracts]
57. Lundahl R.E., Foote R.L., Bonner J.A., et al. Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: a matched-pair analysis. Int J Radiat Oncol Biol Phys 40 (1998) 529-534
58. Gibson M.K., and Forastiere A.A. Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncol 7 (2006) 565-574
59. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
60. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944
61. Harari P.M., Harris J., Kies M.S., et al. Phase II Randomized trial of surgery followed by chemoradiation Plus Cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234). Int J Radiat Oncol Biol Phys 69 (2007) S13
62. Willey C.D., Murphy B.A., Netterville J.L., et al. A Phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients. Int J Radiat Oncol Biol Phys 67 (2007) 1323-1331
63. Hong W.K., Lippman S.M., Itri L.M., et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323 (1990) 795-801
64. Shin D.M., Khuri F.R., Murphy B., et al. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 19 (2001) 3010-3017
65. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 (2005) 341-354
66. Chung C.H., Ely K., McGavran L., et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24 (2006) 4170-4176
67. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 1935-1940
68. Huang S.M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6 (2000) 2166-2174
69. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
70. Kies M.S., Garden A.S., Holsinger C., et al. Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN). J Clin Oncol 24 (2006) 5520 [Meeting Abstracts]
71. Burtness B., Goldwasser M.A., Flood W., Mattar B., and Forastiere A.A. Phase III randomized trial of cisplatin Plus Placebo compared with cisplatin Plus Cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 23 (2005) 8646-8654
72. Pfister D.G., Su Y.B., Kraus D.H., et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24 (2006) 1072-1078
73. Vermorken J., Mesia R., Vega V., et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy-results of a randomized phase III (Extreme) study. J Clin Oncol 25 (2007) (Meeting Abstracts) Abstract # 6091
74. Giusti R.M., Shastri K.A., Cohen M.H., et al. FDA drug approval summary: Panitumumab (VectibixTM). Oncologist 12 (2007) 577-583
75. Wirth L.J., Posner M.R., Tishler R.B., et al. Phase I study of panitumumab, chemotherapy and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): early results. J Clin Oncol 25 (2007) 6083 [Meeting Abstracts]
76. Lee N., Xia P., Fischbein N.J., Akazawa P., Akazawa C., and Quivey J.M. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys 57 (2003) 49-60
77. Lee N., Xia P., Quivey J.M., et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53 (2002) 12-22
78. de Arruda F.F., Puri D.R., Zhung J., et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 64 (2006) 363-373
79. Hunt M.A., Zelefsky M.J., Wolden S., et al. Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys 49 (2001) 623-632
80. Caglar H.B., Allen A.M., Burke E., et al. Swallowing function after intensity modulated radiotherapy (IMRT) and chemotherapy for head and neck cancer. J Clin Oncol 25 (2007) 6046 [Meeting Abstracts]
81. Bar Ad V., Both S., Dutta P., and Quon H. Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck cancers treated with intensity modulated radiation therapy (IMRT). J Clin Oncol 25 (2007) 16513 [Meeting Abstracts]
82. Kwong D.L., McMillan A., Pow E., and Sham J. Value of intensity modulated radiotherapy for local control and salivary flow compared with conventional radiotherapy for stage II nasopharyngeal carcinoma. J Clin Oncol 25 (2007) 6036 [Meeting Abstracts]
83. Allen A.M., and Tishler R.B. Commentary: IMRT for head and neck cancer: many chapters left to write. Oncologist 12 (2007) 565-568
84. Barker Jr. J.L., Garden A.S., Ang K.K., et al. Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys 59 (2004) 960-970
85. Hansen E.K., Bucci M.K., Quivey J.M., Weinberg V., and Xia P. Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 64 (2006) 355-362
86. Ding G.X., Duggan D.M., Coffey C.W., et al. A study on adaptive IMRT treatment planning using kV cone-beam CT. Radiother Oncol 85 (2007) 116-125
87. Lopez M.J., Robinson P., Madden T., and Highbarger T. Nutritional support and prognosis in patients with head and neck cancer. J Surg Oncol 55 (1994) 33-36
88. Brookes G.B. Nutritional status-a prognostic indicator in head and neck cancer. Otolaryngol Head Neck Surg 93 (1985) 69-74
89. Murphy B.A., Friedmann J., Dowling E., Cheatham R., and Cmelak A.J. Dietary intake and adaptations in head and neck cancer patients treated with chemoradiation. Proc Am Soc Clin Oncol 21 (2002) abstract 932
90. Murphy B.A., Wells N., and Dowling E. The Vanderbilt Head and Neck Symptom Survey (VHNSS): a self-report measure of swallowing and nutritional abnormalities. Paper presented at: The Sixth Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer October 9-13 (2002)
91. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 (2000) 3339-3345
92. Amrein P.C., Clark J.R., Supko J.G., et al. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer 104 (2005) 1418-1427
93. Suntharalingam M., Jaboin J., Taylor R., et al. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Semin Oncol 31 (2004) 2-7
94. Murphy B.A., Wells N., Cmelak A.J., et al. Assessment of late effects of chemoradiation on swallowing and nutrition. Adv Head Neck Cancer 2 (2003) 14-18
95. Kotz T., Costello R., Li Y., and Posner M.R. Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head Neck 26 (2004) 365-372
96. McKaig R.G., Baric R.S., and Olshan A.F. Human papillomavirus and head and neck cancer: epidemiology and molecular biology. Head Neck 20 (1998) 250-265
97. Slebos R.J., Yi Y., Ely K., et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 12 (2006) 701-709
98. Chung C.H., Parker J.S., Ely K., et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear Factor-{kappa}B signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 66 (2006) 8210-8218